Xun Wu

Xun Wu

Auto-generated profile, based on publicly available information

Xun Wu

Department of Neurosurgery, Tangdu Hospital, Fourth Military Medical University, Xi’an, 710038 Shaanxi, China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 September 2022 in Science Advances
Verified
Journal Article
Open access
DFDayun Feng
Dayun Feng
JZJinpeng Zhou
Jinpeng Zhou
HLHaixiao Liu
Haixiao Liu
XWXun Wu
Xun Wu
FLFei Li
Fei Li
YQYan Qu
Yan Qu
Blood-brain barrier (BBB) injury critically exacerbates the poor prognosis of patients with subarachnoid hemorrhage (SAH). The massively increased matrix metalloproteinases 9 (MMP-9) plays a deleterious role in BBB. However, the main source and mechanism of MMP-9 production after SAH remain unclear. We reported that the increased MMP-9 was mainly derived from reactive astrocytes after SAH. Ndrg2 knockout in astrocytes inhibited MMP-9 expression after SAH and attenuated BBB damage. Astrocytic Ndrg2 knockout decreased the phosphorylation of Smad2/3 and the transcription of MMP-9. Notably, cytoplasmic NDRG2 bound to the protein phosphatase PPM1A and restricted the dephosphorylation of Smad2/3. Accordingly, TAT-QFNP12, a novel engineered peptide that could block the NDRG2-PPM1A binding and reduce Smad2/3 phosphorylation, decreased astrocytic MMP-9 production and BBB disruption after SAH. In conclusion, this study identified NDRG2-PPM1A signaling in reactive astrocytes as a key switch for MMP-9 production and provided a novel therapeutic avenue for BBB protection after SAH.

28 May 2025 in Science Translational Medicine
Verified
Journal Article
Closed access
WCWenxing Cui
Wenxing Cui
HBHao Bai
Hao Bai
CGChengxuan Guo
Chengxuan Guo
JZJinpeng Zhou
Jinpeng Zhou
DFDayun Feng
Dayun Feng
YQYan Qu
Yan Qu
Astrocyte heterogeneity is closely associated with the pathophysiology of traumatic brain injury (TBI), particularly in the development of cerebral edema, which is a major contributor to morbidity and mortality in patients with TBI. However, little is known about how certain astrocyte subpopulations contribute to the development of cerebral edema after acute brain injury. Using multiomics approaches, we identified a proinflammatory interferon regulatory factor-1–positive (IRF1 + ) astrocyte cluster that correlates with clinical severity and outcomes in patients with TBI. Mechanistically, IRF1 in astrocytes binds to promoters of inflammatory cytokine genes, driving neurotoxicity and disrupting endothelial tight junction integrity. Using Aldh1l1 CreERT2 ; Irf1 flox/flox mice, we demonstrated that astrocyte-specific deletion of Irf1 mitigates astrocyte-mediated pathogenic activities, ameliorates blood-brain barrier (BBB) disruption, and reduces cerebral edema after TBI. Moreover, enhanced IRF1 activity in astrocytes facilitates the recruitment of CD8 + T cells by releasing C-X-C motif chemokine ligand 10 (CXCL10), which exacerbates BBB disruption and cerebral edema. Furthermore, we identified tet methylcytosine dioxygenase 3 (TET3)–mediated DNA hydroxymethylation as a key epigenetic mechanism that up-regulates IRF1 expression in astrocytes, thereby activating proinflammatory transcriptional programs. Finally, we developed an IRF1 antagonist, 8003-3282, which effectively reduces inflammation, preserves BBB integrity, alleviates cerebral edema, and improves neurological outcomes in a TBI mouse model. These findings highlight IRF1 + astrocytes as critical mediators of TBI-associated pathology and suggest that targeting this astrocyte cluster may represent a promising therapeutic strategy to mitigate inflammation, BBB damage, and cerebral edema in TBI.

1 July 2020 in Brain Research
Verified
Journal Article
Closed access
QCQing Cai
Qing Cai
JLJianing Luo
Jianing Luo
SGShunnan Ge
Shunnan Ge
YLYang Li
Yang Li
WCWenxing Cui
Wenxing Cui
DFDayun Feng
Dayun Feng

3 July 2026 in Science Advances
Verified
Journal Article
Open access
JWJiheng Wang
Jiheng Wang
CZChenzhu Zhao
Chenzhu Zhao
BLBei Liu
Bei Liu
ZWZhuoyang Wang
Zhuoyang Wang
YHYueru Hou
Yueru Hou
TZTianzhi Zhao
Tianzhi Zhao
Blood-brain barrier (BBB) disruption is a major pathological feature of traumatic brain injury (TBI) that contributes to secondary damage and poor neurological recovery. Although astrocytes are essential for BBB homeostasis, the molecular basis of astrocyte-associated BBB dysfunction after TBI remains unclear. Here, we found that astrocytic dystrophin protein 71 (Dp71) expression was reduced after TBI in both patients and mouse models. In mice, further experimental down-regulation of astrocytic Dp71 attenuated secondary BBB disruption and was accompanied by reduced astrocyte activation, inflammatory cell infiltration, and matrix metalloproteinase-2 (MMP2) release. Mechanistically, nuclear Dp71 interacted with Wilms tumor 1–associated protein (WTAP) and influenced its ubiquitination, leading to changes in the N 6 -methyladenosine (m 6 A) modification, RNA stability, and expression of MMP2 messenger RNA. In addition, biomimetic nanovesicles coated with astrocyte membranes enabled targeted delivery of small interfering RNA targeting Dp71 (siDp71) to astrocytes and reduced MMP2 release and BBB damage after TBI, suggesting a potential therapeutic strategy for mitigating BBB injury after TBI.